AIM Vaccine Co., Ltd. (the “Group”) announced that its wholly owned subsidiary, AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd., successfully completed on-site inspections for drug clinical trials and drug registration and production for a self-developed serum-free iterative rabies vaccine. According to the Phase III clinical trials, which have already unblinded, this vaccine exhibited good safety, immunogenicity, and immune persistence, meeting the pre-defined clinical evaluation criteria.

The Group has obtained a corresponding production license for this vaccine. Currently, there is no serum-free rabies vaccine approved for launch in the global market. As rabies is a disease with a nearly 100% mortality rate upon symptom onset, prevention through vaccination is crucial. The Group’s serum-free iterative rabies vaccine differs from mainstream serum-containing rabies vaccines, such as the commonly used Vero cell and human diploid rabies vaccines, by eliminating animal serum, substantially improving safety and reducing adverse reactions.

The Group is the world’s second largest supplier of rabies vaccines and has constructed an international-standard serum-free iterative rabies vaccine facility capable of large-scale production. Once this vaccine is approved and commercialized, it is expected to address unfilled global market needs for serum-free rabies prevention. The Group aims to continue advancing rabies vaccine technology and strengthen its position in the global rabies vaccine industry.